

## Transparency Reporting at Kyowa Kirin Methodological Note for 2021 data

### 1. Introduction

Kyowa Kirin AB is committed to supporting healthcare and the development of patient care across the Nordics (Denmark, Sweden, Finland, Norway and Iceland). We are pleased to do this through providing funds to Healthcare Organisations (HCOs) or Healthcare Practitioners (HCPs) and through engaging them for services that contribute to the improvement of patient care. In accordance with EFPIA Disclosure Code, local codes and regulations (i.e. Läkemedelsindustriföreningen (LIF) ethical rules in Sweden, the Association of the Pharmaceutical Industry in Norway (LMI) ethical rules and Pharma Industry Finland (PIF) ethical rules), Kyowa Kirin AB publishes details about transfers of value to these individuals and organisations annually.

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating data in their nation and we make one disclosure per market. This disclosure covers transfers of value between 1<sup>st</sup> January 2021 to 31<sup>st</sup> December 2021 to HCPs and HCOs which are registered in the Nordic countries.

Denmark is exempted from EFPIA Disclosure Code due to local law, and therefore Danish rules and requirements are not in scope or covered in this document. The following covers methodology for the remaining Nordic countries.

No transfer of values are reportable for Iceland for the disclosure cycle 2021.

### 2. Scope of disclosure

This disclosure includes the following transfers of value:

EFPIA Category	EFPIA sub-category	Example activities (not exhaustive)
Donations and grants	N/A	<ul style="list-style-type: none"><li>• Donations to HCOs</li><li>• Educational grants</li><li>• Investigation Sponsored Studies</li></ul>

<b>Contribution to cost of events</b>	Sponsorship agreements	<ul style="list-style-type: none"> <li>Sponsorship of events organised by HCOs or third-parties on their behalf</li> </ul>
	Registration fees	<ul style="list-style-type: none"> <li>Funding of HCPs to attend congresses (only applicable for Finland)</li> </ul>
	Travel and accommodation	<ul style="list-style-type: none"> <li>HCP's travel and accommodation costs for attending congresses (only applicable for Finland)</li> </ul>
<b>Fees for service</b>	Fees	Fees for: <ul style="list-style-type: none"> <li>Chairing or attending Advisory Boards</li> <li>Speaking engagements</li> <li>Medical writing</li> <li>Consultancy</li> </ul>
	Related expenses	Travel and accommodation expenses relating to the activities above.
<b>Research and Development</b>	N/A	Activities relating to: <ul style="list-style-type: none"> <li>planning or conduct of clinical studies</li> <li>clinical trials</li> <li>non-interventional studies that are prospective in nature</li> <li>clinical investigator meetings</li> </ul>

If activities relate to retrospective non-interventional studies, then they are included in Fees for Service, rather than Research and Development.



This disclosure excludes the following transfers of value:

- Hospitality cost (e.g. meals and drinks) unless these are an integral and inseparable part of contributions to the cost of events
- Informational and educational materials and items of medical utility, in line with article 9 of the EFPIA HCP/HCO Disclosure Code
- Logistical costs related to Kyowa Kirin-organised meetings (e.g. room hire)

This disclosure does not include:

- Donations to non-HCOs

Support provided to Patient Organisations is disclosed as according to the regulations of local codes.

Some HCPs continue to provide advice to the healthcare community after they have retired. Generally Kyowa Kirin include such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.

### **3. Date of Transfers of Value**

The date of the transfers of value included in this disclosure is based on date of payment (where the transfer of value is a payment).

If the transfer of value is a benefit in kind, it is based on the date the recipient received the benefit.

### **4. Direct and Indirect Transfers of Value**

For direct transfers of value, the recipient is considered to be the person or entity holding the bank account receiving the money. Kyowa Kirin AB also provides indirect transfers of value.

In the case of payments that are made through Clinical Research Organisations, these are included under Research and Development and reported in the aggregate.

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where third parties are appointed by Kyowa Kirin to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.



## 5. Cross-border activities

Kyowa Kirin makes best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration.

## 6. Consent

In the Nordic countries HCOs are reported without the need for consent as they are legal entities with exception of single-person companies.

HCP's consent is collected at the time of contracting. If consent is not provided, the transfer of value that they have received is included in the aggregate amount. If no response is received a "no" response is assumed and the data is also reported in the aggregate.

## 7. Disclosure

Our report of transfers of value in 2021 is published on affiliate pages found here: [Kyowa Kirin International - Home \(kyowa-kirin.com\)](#) in English or local language if required by local code. For Sweden, the report is published on LIF's homepage: [Lif – de forskande läkemedelsföretagen](#).

The currency used for disclosure is local currency. In the case that payments are made in a currency other than local currency, the payment amount is converted to local currency using the daily exchange rate between the two currencies on the day of payment.

Kyowa Kirin AB discloses transfer of value net amount where possible. If VAT cannot accurately be excluded, the full amount is disclosed. Where income tax or equivalent is withheld by Kyowa Kirin AB on amounts earned by the HCP then the transfer of value will include these amounts.

Data will remain published for 3 years, and stored for a minimum of 5 years by Kyowa Kirin AB. Updates of published data are conducted when necessary to allow for reflection of data updates or consent withdrawal after disclosure submission.

Any questions regarding this disclosure should be directed to [infose@kyowakirin.com](mailto:infose@kyowakirin.com)